{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:08Z","timestamp":1786120328417,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834bb867","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T03:25:00Z","timestamp":1318044300000},"page":"654-658","source":"Crossref","is-referenced-by-count":14,"title":["How to manage thrombosis in myeloproliferative neoplasms"],"prefix":"10.1097","volume":"23","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210128","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythemiaerythrocytosis.","volume":"130","author":"McMullin","year":"2005","journal-title":"Br J Haematol"},{"key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-16-20210128","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2008.177","article-title":"Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.","volume":"22","author":"Finazzi","year":"2008","journal-title":"Leukemia"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The hematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood"},{"key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"R9-16-20210128","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors.","volume":"115","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"R11-16-20210128","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia.","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.V112.11.2803.2803","article-title":"The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPDs).","volume":"112","author":"Kundranda","year":"2008","journal-title":"Blood"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/cncr.24664","article-title":"Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.","volume":"115","author":"Gangat","year":"2009","journal-title":"Cancer"},{"key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","article-title":"Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia.","volume":"7","author":"Passamonti","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R15-16-20210128","first-page":"759","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor B","volume":"114","author":"Barbui","year":"2009","journal-title":"lood"},{"key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","article-title":"Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.","volume":"22","author":"Landolfi","year":"2008","journal-title":"Leukemia"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"R18-16-20210128","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systematic review.","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515WLK mutation in essential thrombocythemia.","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"R21-16-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"R23-16-20210128","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R26-16-20210128","first-page":"286","article-title":"Aspirin in low-risk essential thrombocythemia, not so simple after all Leuk R","volume":"35","author":"Harrison","year":"2011","journal-title":"es"},{"key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"R29-16-20210128","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"R30-16-20210128","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"R31-16-20210128","first-page":"2593","article-title":"Inhibition of tissue factor expression by hydroxyurea in polimorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug J Thromb H","volume":"4","author":"Maugeri","year":"2006","journal-title":"aemost"},{"key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"R35-16-20210128","first-page":"1281","article-title":"Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.","volume":"91","author":"Samuelsson","year":"2006","journal-title":"Haematologica"},{"key":"R36-16-20210128","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32834bb867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:32:17Z","timestamp":1786048337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201111000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834bb867","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}